Windtree Therapeutics Stock Investor Sentiment
| WINT Stock | USD 1.64 0.06 3.53% |
Slightly above 59% of Windtree Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Windtree Therapeutics suggests that many traders are alarmed. Windtree Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Windtree Therapeutics' earnings reports, geopolitical events, and overall market trends.
Windtree |
Windtree Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Windtree Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Windtree Therapeutics that are available to investors today. That information is available publicly through Windtree media outlets and privately through word of mouth or via Windtree internal channels. However, regardless of the origin, that massive amount of Windtree data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Windtree Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Windtree Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Windtree Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Windtree Therapeutics alpha.
Windtree Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Windtree Therapeutics Appoints Leanne Kelly to Board, Advances New Growth Strategy - MyChesCo | 01/17/2025 |
2 | Disposition of 275938 shares by Huang James of Windtree Therapeutics at 12.09 subject to Rule 16b-3 | 01/23/2025 |
3 | Windtree Therapeutics enacts reverse stock split, expands equity plan - Investing.com | 02/03/2025 |
4 | Windtree Therapeutics announces istaroxime presentation on Phase 2b study - TipRanks | 02/12/2025 |
5 | Windtree Therapeutics approves 1-for-50 reverse stock split | 02/18/2025 |
6 | Disposition of 334 shares by Craig Fraser of Windtree Therapeutics subject to Rule 16b-3 | 02/19/2025 |
7 | Disposition of 100 shares by Steven Simonson of Windtree Therapeutics subject to Rule 16b-3 | 02/28/2025 |
8 | WINT Advancing Lead Asset Leveraging Strategic MA to Potentially Shorten Timeline to Revenue Generation Initiating Coverage | 03/04/2025 |
9 | Acquisition by Craig Fraser of 68800 shares of Windtree Therapeutics at 1.21 subject to Rule 16b-3 | 03/07/2025 |
10 | Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product | 03/20/2025 |
11 | Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics - Marketscreener.com | 03/26/2025 |
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.